A prospective head-to-head comparison of -[68Ga]Ga-P16-093 and -[68Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer

被引：12

作者：

Wang, Guochang ^{[1
]}

Li, Linlin ^{[1
]}

Zhu, Ming ^{[2
]}

Zang, Jie ^{[3
]}

Wang, Jiarou ^{[1
]}

Wang, Rongxi ^{[1
]}

Yan, Weigang ^{[2
]}

Zhu, Lin ^{[4
]}

Kung, Hank F. ^{[5
]}

Zhu, Zhaohui ^{[1
]}

机构：

[1] Chinese Acad Med Sci, Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Nucl Med,State Key Lab Complex Severe & Rare, Beijing 100730, Peoples R China

[2] Chinese Acad Med Sci, Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Urol, Beijing 100730, Peoples R China

[3] Fujian Med Univ, Affiliated Hosp 1, Dept Nucl Med, Fuzhou 350005, Peoples R China

[4] Beijing Normal Univ, Minist Educ, Coll Chem, Key Lab Radiopharmaceut, Beijing 100875, Peoples R China

[5] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA

来源：

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2023年 / 50卷 / 10期

基金：

中国国家自然科学基金; 北京市自然科学基金;

关键词：

Ga-68]Ga-P16-093; Ga-68]Ga-PSMA-11; Prostate cancer; PET/CT; MEMBRANE ANTIGEN PSMA; GA-68-PSMA-11; PET/CT; EXPRESSION;

D O I：

10.1007/s00259-023-06283-4

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Purpose We aimed to compare the diagnostic performance and biodistribution of two similar PET agents, -[Ga-68]Ga-P16-093 and -[Ga-68]Ga-PSMA-11, in the same group of primary prostate cancer (PCa) patients. Methods Fifty patients with untreated, histologically confirmed PCa by needle biopsy were enrolled. Each patient underwent -[Ga-68]Ga-P16-093 and -[Ga-68]Ga-PSMA-11 PET/CT within a week. In addition to visual analysis, the standardized uptake value ( SUV) was measured for semiquantitative comparison and correlation analysis. Results [Ga-68]Ga-P16-093 PET/CT detected more positive tumors than -[Ga-68]Ga-PSMA-11 PET/CT (202 vs. 190, P = 0.002), both for intraprostatic lesions (48 vs. 41, P = 0.016) and metastatic lesions (154 vs. 149, P = 0.125), especially for intraprostatic lesions in low- and intermediate-risk PCa patients (21/23 vs. 15/23, P = 0.031). Furthermore, -[Ga-68]Ga-P16-093 PET/CT exhibited a significantly higher SUVmax for most matched tumors (13.7 +/- 10.2 vs. 11.4 +/- 8.3, P < 0.001). For normal organs, -[Ga-68]Ga-P16-093 PET/CT showed significantly lower activity in the kidney (SUVmean: 20.1 +/- 6.1 vs. 29.3 +/- 9.1, P < 0.001) and urinary bladder (SUVmean: 6.5 +/- 7.1 vs. 20.9 +/- 17.4, P < 0.001), but displayed a higher uptake in the parotid gland (SUVmean: 8.7 +/- 2.6 vs. 7.6 +/- 2.1, P < 0.001), liver ( SUVmean: 7.0 +/- 1.9 vs. 3.7 +/- 1.3, P < 0.001), and spleen (SUVmean: 8.2 +/- 3.0 vs. 5.2 +/- 2.2, P < 0.001) than -[Ga-68]Ga-PSMA-11 PET/CT. Conclusion [Ga-68] Ga-P16-093 PET/CT demonstrated higher tumor uptake and better tumor detectability than -[Ga-68]GaPSMA-11 PET/CT, especially in low- and intermediate-risk PCa patients, which indicated that -[Ga-68]Ga-P16-093 may serve as an alternative agent for detection of PCa. Trial registration Ga-68-P16-093 and Ga-68-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients (NCT05324332, Registered 12 April 2022, retrospectively registered).

引用

页码：3126 / 3136

页数：11

共 31 条

[11] Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study [J].

Hofman, Michael S. ;

Lawrentschuk, Nathan ;

Francis, Roslyn J. ;

Tang, Colin ;

Vela, Ian ;

Thomas, Paul ;

Rutherford, Natalie ;

Martin, Jarad M. ;

Frydenberg, Mark ;

Shakher, Ramdave ;

Wong, Lih-Ming ;

Taubman, Kim ;

Lee, Sze Ting ;

Hsiao, Edward ;

Roach, Paul ;

Nottage, Michelle ;

Kirkwood, Ian ;

Hayne, Dickon ;

Link, Emma ;

Marusic, Petra ;

Matera, Anetta ;

Herschtal, Alan ;

Iravani, Amir ;

Hicks, Rodney J. ;

Williams, Scott ;

Murphy, Declan G. .

LANCET, 2020, 395 (10231) :1208-1216

[12] Molecular imaging with 68Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours [J].

Kaemmerer, Daniel ;

Peter, Luisa ;

Lupp, Amelie ;

Schulz, Stefan ;

Saenger, Joerg ;

Prasad, Vikas ;

Kulkarni, Harshad ;

Haugvik, Sven-Petter ;

Hommann, Merten ;

Baum, Richard Paul .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (09) :1659-1668

[13] 68Ga-PSMA PET/CT for Primary Lymph Node and Distant Metastasis NM Staging of High-Risk Prostate Cancer [J].

Klingenberg, Soren ;

Jochumsen, Mads R. ;

Ulhoi, Benedicte P. ;

Fredsoe, Jacob ;

Sorensen, Karina D. ;

Borre, Michael ;

Bouchelouche, Kirsten .

JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (02) :214-220

[14] Head-to-Head Comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard [J].

Kuten, Jonathan ;

Fahoum, Ibrahim ;

Savin, Ziv ;

Shamni, Ofer ;

Gitstein, Gilad ;

Hershkovitz, Dov ;

Mabjeesh, Nicola J. ;

Yossepowitch, Ofer ;

Mishani, Eyal ;

Even-Sapir, Einat .

JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (04) :527-532

[15] Preliminary Evaluation of 68Ga-P16-093, a PET Radiotracer Targeting Prostate-Specific Membrane Antigen in Prostate Cancer [J].

Lee, Hwan ;

Scheuermann, Joshua S. ;

Young, Anthony J. ;

Doot, Robert K. ;

Daube-Witherspoon, Margaret E. ;

Schubert, Erin K. ;

Fillare, Matthew A. ;

Alexoff, David ;

Karp, Joel S. ;

Kung, Hank F. ;

Pryma, Daniel A. .

MOLECULAR IMAGING AND BIOLOGY, 2022, 24 (05) :710-720

[16] FDA Approves Ga 68 PSMA-11 for Prostate Cancer Imaging [J].

Masters, Shane C. ;

Hofting, Alex ;

Gorovets, Alex ;

Marzella, Libero .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (01) :27-28

[17] Prostate Cancer, Version 2.2019 [J].

Mohler, James L. ;

Antonarakis, Emmanuel S. ;

Armstrong, Andrew J. ;

D'Amico, Anthony, V ;

Davis, Brian J. ;

Dorff, Tanya ;

Eastham, James A. ;

Enke, Charles A. ;

Farrington, Thomas A. ;

Higano, Celestia S. ;

Horwitz, Eric Mark ;

Hurwitz, Michael ;

Ippolito, Joseph E. ;

Kane, Christopher J. ;

Kuettel, Michael R. ;

Lang, Joshua M. ;

McKenney, Jesse ;

Netto, George ;

Penson, David F. ;

Plimack, Elizabeth R. ;

Pow-Sang, Julio M. ;

Pugh, Thomas J. ;

Richey, Sylvia ;

Roach, Mack, III ;

Rosenfeld, Stan ;

Schaeffer, Edward ;

Shabsigh, Ahmad ;

Small, Eric J. ;

Spratt, Daniel E. ;

Srinivas, Sandy ;

Tward, Jonathan ;

Shead, Dorothy A. ;

Freedman-Cass, Deborah A. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (05) :479-505

[18] Impact of PET acquisition durations on image quality and lesion detectability in whole-body 68Ga-PSMA PET-MRI [J].

Noto, Benjamin ;

Buether, Florian ;

Springe, Katharina Auf Der ;

Avramovic, Nemanja ;

Heindel, Walter ;

Schaefers, Michael ;

Allkemper, Thomas ;

Stegger, Lars .

EJNMMI RESEARCH, 2017, 7

[19] Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate Cancer [J].

Park, Sonya Youngju ;

Zacharias, Claudia ;

Harrison, Caitlyn ;

Fan, Richard E. ;

Kunder, Christian ;

Hatami, Negin ;

Giesel, Frederik ;

Ghanouni, Pejman ;

Daniel, Bruce ;

Loening, Andreas M. ;

Sonn, Geoffrey A. ;

Iagaru, Andrei .

RADIOLOGY, 2018, 288 (02) :495-505

[20]

Pattison DA, 2022, EUR J NUCL MED MOL I, V49, P763, DOI 10.1007/s00259-021-05520-y

← 1 2 3 4 →